Sanofi, Drug Prices & Medicare Spending

Sanofi manufactures 15 drugs tracked by Medicare Part D with total spending of $8.0B.

Drugs Tracked

$8.0B

Medicare Spending

$143.88

Avg Cost/Claim

100%

Have Generics

Sanofi Drugs, Ranked by Medicare Spending

#	Drug	Generic Name	Cost/Claim	Medicare Spending	YoY Change	Generic?
1	Lantus	Insulin Glargine	$136.00	$2.0B	-18.6%	Yes
2	Aubagio	Teriflunomide	$3,363.00	$1.3B	-5.6%	Yes
3	Toujeo	Insulin Glargine U-300	$254.00	$1.2B	-8.4%	Yes
4	Eloctate	Antihemophilic Factor (FC fusion)	$31,500.00	$567.0M	-4.6%	Yes
5	Sarclisa	Isatuximab	$14,250.00	$456.0M	+28.9%	Yes
6	Lovenox	Enoxaparin	$94.00	$456.0M	-14.2%	Yes
7	Renvela	Sevelamer Carbonate	$71.00	$345.0M	-18.4%	Yes
8	Alprolix	Coagulation Factor IX (FC fusion)	$28,750.00	$345.0M	-8.4%	Yes
9	Soliqua	Insulin Glargine/Lixisenatide	$375.00	$234.0M	+4.2%	Yes
10	Admelog	Insulin Lispro (biosimilar)	$139.00	$234.0M	-14.2%	Yes
11	Dronedarone	Dronedarone	$189.00	$234.0M	-4.2%	Yes
12	Multaq	Dronedarone HCl	$189.00	$234.0M	-4.6%	Yes
13	Lemtrada	Alemtuzumab	$14,833.00	$178.0M	-14.2%	Yes
14	Furosemide	Furosemide	$6.00	$89.0M	-12.4%	Yes
15	Zolpidem	Zolpidem Tartrate	$14.00	$89.0M	-28.4%	Yes

Frequently Asked Questions

Sanofi manufactures 15 drugs tracked by Medicare Part D, with total annual spending of $8.0B.

Eloctate (Antihemophilic Factor (FC fusion)) is the most expensive at $31,500.00 per claim.

15 of 15 Sanofi drugs (100%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.

this entity is one of the data points covered by this site’s U.S. Medicare prescription-drug pricing dataset. The detail above comes directly from CMS Medicare Part D Drug Spending data; the context that follows situates the headline numbers against the broader distribution across U.S. prescription drugs.

Every number on this page links back to CMS Medicare Part D Drug Spending data; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within U.S. prescription drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.

Source: CMS Medicare Part D Spending, 2026.